Caribou Biosciences to Participate in Upcoming Investor Conferences
BERKELEY, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following investor conferences:
- Barclays Gene Editing & Gene Therapy Summit, Virtual
Panel participation on November 14, 2022 at 11:00 am EST
- Jefferies London Healthcare Conference, London, United Kingdom
Corporate presentation on November 17, 2022 at 3:50 pm GMT
- 5th Annual Evercore ISI HealthCONx Conference, Virtual
Fireside chat on November 30, 2022 at 11:45 am EST
- BofA Securities Biotech SMID Cap Conference, Boston
Fireside chat on December 7, 2022 at 10:50 am EST
Webcast to be made available on page
For more information, visit the page on Caribou’s website. The webcasts will be available on the Caribou website for 30 days after the events.
About Caribou’s Novel Next-Generation CRISPR Platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.
About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors.
For more information about Caribou, visit and follow the company @CaribouBio.
“Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
Caribou Biosciences, Inc. Contacts:
Investors:
Amy Figueroa, CFA
Media:
Peggy Vorwald, Ph.D.
Investors and Media:
Elizabeth Wolffe, Ph.D., and Sylvia Wheeler
Wheelhouse LSA
